Saturday, October 17, 2026 · Edition updated 6:00 AM ETSAT, OCT 17 · 6 AM ET editionNext edition in Next --:--:--

Muscle health and heart markers in older adults hospitalized for heart failure

Recruiting · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

What this means

Researchers plan to track 110 adults aged 80 or older after a heart failure stay for six months. The study is still recruiting, so it does not yet show whether these measures predict outcomes.

Plain-English summary written by an AI model from the registry listing.

Status
Recruiting
Who can join
Ages 80 and over · 110 patients aged 80 or older hospitalized for acute heart failure
Where
1 site

Contacts and how to join ↗

The science

Registered title
Sarcopenia in Older Patients Hospitalized for Acute Heart Failure.
Phase
Not applicable
Study type
observational
Conditions
Acute Heart Failure (AHF), Sarcopenia, Heart Failure
Sponsor
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Ages
80 Years to no maximum
Dates
First posted Apr 14, 2026 · updated Jun 23, 2026

Registry summary

Acute heart failure (AHF) is the leading cause of hospitalization in people over 65, with the group with preserved ejection fraction (HFpEF) being the most closely related to aging. Among its comorbidities, sarcopenia stands out, and its assessment requires measurement of muscle mass. Muscle ultrasound is an accessible and economical alternative, although its prognostic value is still uncertain. The presence of common pathophysiological mechanisms between HF-PEF and sarcopenia leads to the study of biomarkers to improve their characterization.

Multimodal characterization of sarcopenia, integrating muscle mass and strength with skeletal and cardiac muscle biomarkers, will improve prognostic stratification at discharge in elderly patients with HFpEF hospitalized for ACS. We seek to evaluate the prognostic value of muscle mass estimated by ultrasound, in combination with strength measurements and circulating biomarkers related to sarcopenia, as this could improve the prediction of clinical events after hospitalization for AHF in elderly patients with HFpEF. In addition, ultrasound estimation of muscle mass will be analyzed against BIA, the relationship between skeletal and cardiac muscle will be characterized, and the usefulness of the multimodal approach to sarcopenia will be evaluated.

This study is observational, prospective, and single-center. It will include 110 patients hospitalized for AHF aged ≥80 years. Events will be monitored for 6 months after discharge. Variables include clinical data, ultrasound data (lung, VExUS, and muscle mass), congestion markers (BNP, CA125), biomarkers (GDF-15, sST2, BDNF, and myostatin/follistatin), bioimpedance, and dynamometry. Data will be analyzed using regression models and survival analysis to identify prognostic factors.

This study has the potential to improve the clinical management of patients with acute heart failure by providing key information on its interaction with sarcopenia. The results could help identify more effective strategies to reduce rehospitalization and mortality in these patients, improving their prognosis and quality of life.

Sites (1)

  • Hospital Universitario Ramon y Cajal, Madrid, Madrid, Spain
Report a problem